Cytokines Behavior in Multiple Myeloma Patients during Zoledronic Acid Treatment
Received Date: Nov 27, 2017 / Accepted Date: Nov 30, 2017 / Published Date: Dec 02, 2017
Objective: Multiple Myeloma (MM) is characterized by uncoupling of bone resorption from bone formation which leads to the predominance of resorption. Bisphosphonates are chemical compounds that selectively concentrate at the interface of the active osteoclasts and the bone resorption surface where they inhibit osteoclast activity. Aim of this study was to describe cytokines behaviour in MM and to evaluate whether zoledronic acid could have an in vivo anti-angiogenic property in MM as observed in solid tumours.
Methods: Serum samples from 29 (16 males and 13 females) consecutive MM patients with lytic bone lesions treated with 4 mg of zoledronic acid were tested for platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), tumor necrosis factor (TNF α) and insulin growth factor (IGF-I). Basal cytokine levels were compared with the values observed after 1, 2, 7 and 21 days of treatment, using the Wilcoxon’s test for nonparametric-dependent continuous variables.
Results: A significant increase in IL-6 and TNF α was observed on days 1 and 2. As for VEGF, the levels of this cytokine did not change significantly from basal values during the entire period of observation except for a significant increase day 7 (P=0.0005). Moreover, PDGF significantly decreased (P=0.005) after 2 days from zoledronic acid infusion.
Conclusions: From this study appears that in MM, treatment with zoledronic acid induces a transient reduction in PDGF according with previous studies in solid cancer, while the increase of IL-6 and VEGF could be related through a paracrine mechanism. The anti-myeloma effect of this drug could be driven through this mechanism.
Keywords: Zoledronic acid; Multiple myeloma; Cytokines; Angiogenesis
Citation: Annibali O, Petrucci MT, Tirindelli MC, Giannetti B, Vincenzi B, et al. (2017) Cytokines Behavior in Multiple Myeloma Patients during Zoledronic Acid Treatment. J Blood Lymph 7: 184. Doi: 10.4172/2165-7831.1000184
Copyright: © 2017 Annibali O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 1541
- [From(publication date): 0-2017 - Dec 11, 2019]
- Breakdown by view type
- HTML page views: 1467
- PDF downloads: 74